Emmanuel Jean-Marie Mignot, MD
Sleep Medicine · Stanford
- Medicare standing
- Clear
- Enrolled, allowed to bill and order, not excluded
- Plans that list them
- 10
- 2 carriers
- Offices
- 3
Offices
3 locations · Stanford Health Care · 3,152 clinicians in this group
Looking this up.
Plans that list them
10 plans · 2 carriers
A missing listing does not mean out of network. Directories change, and a listing does not cover every office. Call Dr. Mignot’s office at (650) 723-4000 to confirm they take your plan. Ask about the office you use, its medical group, referrals and appointments.
10 of 10 plans
| Alignment Health BreathEasy (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Clarity (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Harmony (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes CalPlus (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes Care (HMO C-SNP) | Alignment Health Plan | Listed | Sep 28, 2026 |
| Alignment Health Heart & Diabetes Choice (HMO C-SNP) | Alignment Health Plan | Listed | Sep 28, 2026 |
| Alignment Health Honor+ Plan (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health My Choice CalCare (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| DualConnect (HMO D-SNP) | Santa Clara Family Health Plan | Listed | Sep 1, 2026 |
California Medical Board record
Licence A67085 · Current
Licensed to practise in California · since 1998 · expires 2026-12-31 · University Rene Descartes (Paris V) U.F.R. of Medicine Cochin-Port Royal.
No disciplinary actions, convictions, malpractice judgments or citations in this record.
Money from drug and device companies
$47,971 in 2025
| 2025 | 7 | 26 | $39,816 | $47,971 |
| 2024 | 5 | 22 | $26,673 | $40,599 |
| 2023 | 3 | 9 | $4,250 | $4,566 |
| 2022 | 3 | 7 | $2,400 | $2,845 |
| 2021 | 3 | 17 | $22,303 | $23,131 |
| 2020 | 2 | 5 | $14,160 | $14,160 |
| 2019 | 3 | 9 | None | $1,292 |
Paid work is consulting, speaking, honoraria and royalties, as opposed to meals and travel.
A payment is not proof that care is biased.
| Takeda Pharmaceuticals U.S.A. | None | $27,549 | 14 payments
|
| Avadel CNS Pharmaceuticals | Lumryz | $11,180 | 3 payments
|
| Alkermes | Aristada | $4,743 | 5 payments
|
| Eisai | None | $3,000 | 1 payment
|
| Sanofi US Services | None | $1,324 | 1 payment
|
| Jazz Pharmaceuticals | Xyrem | $138 | 1 payment
|
See all 26 published payments
| Alkermes | Consulting · 2025-11-24 | None | $1,675 |
| Takeda Pharmaceuticals U.S.A. | Meals · 2025-11-11 | None | $90 |
| Takeda Pharmaceuticals U.S.A. | Consulting · 2025-11-07 | None | $1,500 |
| Alkermes | Consulting · 2025-10-14 | Aristada | $1,340 |
| Alkermes | Consulting · 2025-10-06 | Aristada | $1,650 |
| Alkermes | Meals · 2025-09-20 | None | $19 |
| Alkermes | Meals · 2025-09-20 | None | $59 |
| Takeda Pharmaceuticals U.S.A. | Meals · 2025-09-20 | None | $35 |
| Takeda Pharmaceuticals U.S.A. | Meals · 2025-08-19 | None | $73 |
| Takeda Pharmaceuticals U.S.A. | Meals · 2025-08-18 | None | $78 |
| Takeda Pharmaceuticals U.S.A. | Consulting · 2025-07-25 | None | $6,300 |
| Sanofi US Services | Consulting · 2025-07-02 | None | $1,324 |
| Axsome Therapeutics | Meals · 2025-06-10 | None | $37 |
| Jazz Pharmaceuticals | Meals · 2025-06-08 | Xyrem | $138 |
| Takeda Pharmaceuticals U.S.A. | Meals · 2025-06-07 | None | $87 |
| Eisai | Consulting · 2025-06-04 | None | $3,000 |
| Takeda Pharmaceuticals U.S.A. | Meals · 2025-05-21 | None | $2 |
| Takeda Pharmaceuticals U.S.A. | Meals · 2025-05-20 | None | $107 |
| Takeda Pharmaceuticals U.S.A. | Consulting · 2025-05-09 | None | $3,000 |
| Takeda Pharmaceuticals U.S.A. | Meals · 2025-03-14 | None | $66 |
| Takeda Pharmaceuticals U.S.A. | Paid to speak or teach · 2025-02-07 | None | $10,422 |
| Avadel CNS Pharmaceuticals | Meals · 2025-01-21 | None | $39 |
| Avadel CNS Pharmaceuticals | Consulting · 2025-01-15 | Lumryz | $3,815 |
| Avadel CNS Pharmaceuticals | Travel · 2025-01-15 | Lumryz | $7,326 |
| Takeda Pharmaceuticals U.S.A. | Consulting · 2025-01-03 | None | $2,895 |
| Takeda Pharmaceuticals U.S.A. | Consulting · 2025-01-03 | None | $2,895 |
See earlier years (2024, 2023, 2022, 2021, 2020, 2019)
2024: $40,599
| Takeda Pharmaceuticals U.S.A. | None | $36,695 | 12 payments
|
| Daiichi Sankyo | None | $1,865 | 4 payments
|
| Harmony Biosciences | Wakix | $1,563 | 1 payment
|
| Jazz Pharmaceuticals | Xyrem | $326 | 3 payments
|
| Idorsia Pharmaceuticals US | Quviviq | $150 | 2 payments
|
2023: $4,566
| Takeda Pharmaceuticals U.S.A. | None | $3,668 | 5 payments
|
| Jazz Pharmaceuticals | Xyrem | $798 | 2 payments
|
| Axsome Therapeutics | Sunosi | $99 | 2 payments
|
2022: $2,845
| Takeda Pharmaceuticals U.S.A. | None | $2,672 | 5 payments
|
| Jazz Pharmaceuticals | Xyrem | $150 | 1 payment
|
| Harmony Biosciences | Wakix | $23 | 1 payment
|
2021: $23,131
| Takeda Pharmaceuticals U.S.A. | None | $11,053 | 4 payments
|
| Eisai | Dayvigo | $10,729 | 12 payments
|
| Harmony Biosciences | Wakix | $1,350 | 1 payment
|
2020: $14,160
| Jazz Pharmaceuticals | Xyrem | $12,960 | 4 payments
|
| Philips Electronics North America | (2383) Sleepundivided | $1,200 | 1 payment
|
2019: $1,292
| Merck Sharp & Dohme | None | $1,039 | 7 payments
|
| Philips Electronics North America | Src Und | $197 | 1 payment
|
| Jazz Pharmaceuticals | Xyrem | $56 | 1 payment
|
Research money
Money a company paid to run a study. Where it went to their institution, the clinician is named as an investigator and did not receive it; the amount covers the whole study, often across many sites.
| Takeda Pharmaceuticals U.S.A., Inc. · Tak-861-3001 A Study To Evaluate the Efficacy and Safety of Tak-861 for the Treatment of Narcolepsy With Cataplexy · 2025 | Their institution | $707,813 |
| Alkermes, Inc. · A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods To Evaluate the Safety and Efficacy of Alks 2680 in Subjects With Narcolepsy Type 1 · 2025 | Their institution | $432,969 |
| Takeda Pharmaceuticals U.S.A., Inc. · A Randomized, Double-Blind, Placebo-Controlled Study To Evaluate the Efficacy, Safety, and Tolerability of Tak-861 for the Treatment of Narcolepsy Without Cataplexy (Narcolepsy Type 2) · 2024 | Their institution | $359,321 |
| JAZZ PHARMACEUTICALS INC. · A Prospective, Open-Label, Single-Arm, Multicenter Study To Evaluate the Effect of Low-Sodium Oxybate Oral Solution (Xywav) on Sleepiness, Polysomnography, and Functional Outcomes in Adult Participants Aged 18 To 75 Years With Idiopathic Hypersomnia Or Narcolepsy · 2025 | Their institution | $322,264 |
| Alkermes, Inc. · An Open-Label, Long-Term Extension Study To Investigate the Safety, Tolerability, and Durability of Treatment Effect of Alks 2680 in Subjects With Narcolepsy Type 1 and Type 2 and Idiopathic Hypersomnia · 2025 | Their institution | $224,372 |
| Eisai Inc. · Lemborexant in Delayed Sleep Phase Syndrome · 2024 | Their institution | $210,348 |
| Takeda Pharmaceuticals U.S.A., Inc. · A Long-Term Extension Study To Evaluate the Safety and Tolerability of Tak-861 in Participants With Selected Central Hypersomnia Conditions · 2025 | Their institution | $172,490 |
| Takeda Pharmaceuticals U.S.A., Inc. · A Long-Term Extension Study To Evaluate the Safety and Tolerability of Tak-861 in Participants With Selected Central Hypersomnia Conditions · 2024 | Their institution | $169,586 |
| Alkermes, Inc. · A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods To Evaluate the Safety and Efficacy of Alks 2680 in Subjects With Narcolepsy Type 2 · 2025 | Their institution | $161,763 |
| JAZZ PHARMACEUTICALS INC. · A Prospective, Open-Label, Single-Arm, Multicenter Study To Evaluate the Effect of Low-Sodium Oxybate Oral Solution (Xywav) on Sleepiness, Polysomnography, and Functional Outcomes in Adult Participants Aged 18 To 75 Years With Idiopathic Hypersomnia Or Narcolepsy · 2024 | Their institution | $151,913 |
| Takeda Pharmaceuticals U.S.A., Inc. · A Randomized, Double-Blind, Placebo-Controlled, Multiple Rising Oral Dose Study To Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Tak-994 in Patients With Narcolepsy With Or Without Cataplexy (Narcolepsy Type 1 Or Narcolepsy Type 2) · 2021 | Their institution | $143,423 |
| Alkermes, Inc. · A Phase 2, Randomized, Parallel-Group, Double-Blind, Dose-Range-Finding Study To Evaluate the Safety and Efficacy of Alks 2680 in Subjects With Idiopathic Hypersomnia (Vibrance 3) · 2025 | Their institution | $137,978 |
| Takeda Pharmaceuticals U.S.A., Inc. · A Dose-Finding, Adaptive, Randomized, Double-Blinded, Placebo-Controlled Study To Evaluate the Safety, Tolerability, and Efficacy of Tak-360 in Participants With Idiopathic Hypersomnia (Ih) · 2025 | Their institution | $111,639 |
| Merck Sharp & Dohme Corporation · Clinical Trial To Characterize Symptoms of Excessive Daytime Sleepiness Following Treatment Withdrawal in Participants With Narcolepsy Type 1 · 2020 | Their institution | $97,983 |
| Takeda Pharmaceuticals U.S.A., Inc. · Improving on the Detection of Narcolepsy Through Nocturnal Psg Analysis and Establishing A Sensitive Biomarker for Orexin Pharmacological Responses · 2021 | Their institution | $93,513 |
| Takeda Pharmaceuticals U.S.A., Inc. · A Randomized, Double-Blind, Placebo-Controlled Study To Evaluate the Efficacy, Safety, and Tolerability of Tak-861 for the Treatment of Narcolepsy Without Cataplexy (Narcolepsy Type 2) · 2023 | Their institution | $84,120 |
| JAZZ PHARMACEUTICALS INC. · A Phase 4 Multicenter Open-Label Single-Arm Study of Safety Tolerability Effectiveness and Treatment Optimization in Participants Switching From Xyrem To Xywav for the Treatment of Narcolepsy · 2022 | Their institution | $74,797 |
| JAZZ PHARMACEUTICALS INC. · Protein Biomarkers of T1, T2 Narcolepsy and Idiopathic Hypersomnia (Preclinical) · 2024 | Their institution | $62,939 |
| Eisai Inc. · Lemborexant in Delayed Sleep Phase Syndrome · 2025 | Their institution | $57,635 |
| Takeda Pharmaceuticals U.S.A., Inc. · A Dose-Blind Extension Study With Double-Blind, Placebo-Controlled, Randomized Withdrawal Period To Evaluate the Safety and Explore the Pharmacokinetics and Pharmacodynamics of Tak-994 in Adults With Narcolepsy With Cataplexy (Narcolepsy Type 1) · 2021 | Their institution | $56,000 |
| Takeda Pharmaceuticals U.S.A., Inc. · A Study To Assess the Frequency and Characteristics of Wake and Sleep State Transitions Over Multiple Nights in Subjects With Narcolepsy Type 1 Compared With Healthy Subjects Using A Portable Electroencephalogram Device · 2021 | Their institution | $52,717 |
| Takeda Pharmaceuticals U.S.A., Inc. · A Randomized, Double-Blind, Placebo-Controlled, Multiple Rising Oral Dose Study To Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Tak-994 in Patients With Narcolepsy With Or Without Cataplexy (Narcolepsy Type 1 Or Narcolepsy Type 2) · 2023 | Their institution | $51,996 |
| Takeda Pharmaceuticals U.S.A., Inc. · Improving on the Detection of Narcolepsy Through Nocturnal Psg Analysis and Establishing A Sensitive Biomarker for Orexin Pharmacological Responses · 2022 | Their institution | $50,000 |
| Takeda Pharmaceuticals U.S.A., Inc. · A Study of Tak-360 in Adults With Narcolepsy Without Cataplexy (Nt2) · 2025 | Their institution | $47,791 |
| Takeda Pharmaceuticals U.S.A., Inc. · Tak-994-1504 Open Label Extension · 2023 | Their institution | $44,343 |
| JAZZ PHARMACEUTICALS INC. · A Phase 4 Multicenter, Open-Label, Single-Arm Study of Safety, Tolerability, Effectiveness and Treatment Optimization in Participants Switching From Xyrem To Xywav for the Treatment of Narcolepsy · 2023 | Their institution | $41,239 |
| Eisai Inc. · Lemborexant in Delayed Sleep Phase Syndrome · 2023 | Their institution | $39,272 |
| JAZZ PHARMACEUTICALS INC. · Jzp080-301 A Double-Blind, Placebo-Controlled, Ramdomized Withdrawal, Multicenter Study of the Efficacy and Safety of Jzp-258 in the Treatment of Idiopathic Hypersommnia (Ih) With An Open-Label Safety Extention · 2020 | Their institution | $35,771 |
| JAZZ PHARMACEUTICALS INC. · An Open-Label, Multicenter Switch Study Evaluating Changes in Blood Pressure in Participants With Narcolepsy Switching From High-Sodium Oxybate To Xywav · 2024 | Their institution | $27,897 |
| Takeda Pharmaceuticals U.S.A., Inc. · A Phase 1b Randomized, Double-Blind, Placebo-Controlled, Crossover Study of A Single Intravenous Infusion Dose of Tak-925 in Patients With Idiopathic Hypersomnia · 2020 | Their institution | $26,976 |
| JAZZ PHARMACEUTICALS INC. · A Double-Blind, Placebo-Controlled, Randomized-Withdrawal, Multicenter Study of the Efficacy and Safety of Xyrem With An Open-Label Pharmacokinetic Evaluation and Safety Extension in Pediatric Subjects With Narcolepsy With Cataplexy · 2019 | Their institution | $26,316 |
| JAZZ PHARMACEUTICALS INC. · An Open-Label, Multicenter Switch Study Evaluating Changes in Blood Pressure in Participants With Narcolepsy Switching From High-Sodium Oxybate To Xywav · 2025 | Their institution | $25,165 |
| JAZZ PHARMACEUTICALS INC. · A Double-Blind, Placebo-Controlled, Randomized Withdrawal, Multicenter Study of the Efficacy and Safety of Jzp-258 in the Treatment of Idiopathic Hypersomnia (Ih) With An Open-Label Safety Extension · 2020 | Their institution | $24,552 |
| Merck Sharp & Dohme Corporation · Clinical Trial To Characterize Symptoms of Excessive Daytime Sleepinessfollowing Treatment Withdrawal in Participants With Narcolepsy Type 1. · 2019 | Their institution | $24,432 |
| Takeda Pharmaceuticals U.S.A., Inc. · A Randomized, Double-Blind, Placebo-Controlled, Multiple Rising Oral Dose Study To Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Tak-994 in Patients With Narcolepsy With Or Without Cataplexy (Narcolepsy Type 1 Or Narcolepsy Type 2) · 2020 | Their institution | $23,520 |
| Takeda Pharmaceuticals U.S.A., Inc. · A Dose-Blind Extension Study With Double-Blind, Placebo-Controlled, Randomized Withdrawal Period To Evaluate the Safety and Explore the Pharmacokinetics and Pharmacodynamics of Tak-994 in Adults With Narcolepsy With Cataplexy (Narcolepsy Type 1) · 2022 | Their institution | $21,661 |
| JAZZ PHARMACEUTICALS INC. · A Multicenter Study of the Efficacy and Safety of Jzp-258 in the Treatment of Idiopathic Hypersomnia (Ih) With An Open-Label Safety Extension · 2019 | Their institution | $16,732 |
| Takeda Pharmaceuticals U.S.A., Inc. · A Randomized, Double-Blind, Placebo-Controlled, Multiple Rising Oral Dose Study To Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Tak-994 in Patients With Narcolepsy With Or Without Cataplexy (Narcolepsy Type 1 Or Narcolepsy Type 2) · 2022 | Their institution | $15,526 |
| Vanda Pharmaceuticals Inc. · Evaluating the Effects of Tasimelteon Vs. Placebo in Delayed Sleep-Wake Phase Disorder (Dswpd) · 2022 | Their institution | $13,958 |
| HARMONY BIOSCIENCES LLC · A Double-Blind, Placebo-Controlled, Randomized Withdrawal Study To Evaluate the Safety and Efficacy of Pitolisant in Adult Patients With Idiopathic Hypersomnia · 2024 | Their institution | $13,670 |
| Merck Sharp & Dohme Corporation · Clinical Trial To Characterize Symptoms of Excessive Daytime Sleepiness Following Treatment Withdrawal in Participants With Narcolepsy Type 1 · 2021 | Their institution | $12,332 |
| Alkermes, Inc. · A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods To Evaluate the Safety and Efficacy of Alks 2680 in Subjects With Narcolepsy Type 2 · 2024 | Their institution | $11,499 |
| Alkermes, Inc. · A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods To Evaluate the Safety and Efficacy of Alks 2680 in Subjects With Narcolepsy Type 1 · 2024 | Their institution | $9,139 |
| Vanda Pharmaceuticals Inc. · Evaluating the Effects of Tasimelteon Vs. Placebo in Delayed Sleep-Wake Phase Disorder (Dswpd) · 2023 | Their institution | $9,124 |
| Merck Sharp & Dohme LLC · Clinical Trial To Characterize Symptoms of Excessive Daytime Sleepiness Following Treatment Withdrawal in Participants With Narcolepsy Type 1 · 2023 | Their institution | $5,294 |
| JAZZ PHARMACEUTICALS INC. · A Multicenter Study of the Efficacy and Safety of Jzp-258 in the Treatment of Idiopathic Hypersomnia (Ih) With An Open-Label Safety Extension · 2020 | Their institution | $5,264 |
| Takeda Pharmaceuticals U.S.A., Inc. · A Randomized, Double-Blind, Placebo-Controlled, Multiple Rising Oral Dose Study To Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Tak-994 in Patients With Narcolepsy With Or Without Cataplexy (Narcolepsy Type 1 Or Narcolepsy Type 2) · 2024 | Their institution | $5,004 |
| JAZZ PHARMACEUTICALS INC. · A Double-Blind, Placebo-Controlled, Randomized Withdrawal, Multicenter Study of the Efficacy and Safety of Jzp-258 in the Treatment of Idiopathic Hypersomnia (Ih) With An Open-Label Safety Extension · 2021 | Their institution | $3,371 |
| Takeda Pharmaceuticals U.S.A., Inc. · A Randomized, Double-Blind, Placebo-Controlled, Multiple Rising Oral Dose Study To Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Tak-994 in Patients With Narcolepsy With Or Without Cataplexy (Narcolepsy Type 1 Or Narcolepsy Type 2) · 2020 | This clinician | $1,843 |
| Takeda Pharmaceuticals U.S.A., Inc. · A Phase 1b Randomized, Double-Blind, Placebo-Controlled, Crossover Study of 2 Single Intravenous Infusion Doses of Tak-925 in Subjects With Obstructive Sleep Apnea Who Are Experiencing Excessive Daytime Sleepiness Despite Adequate Use of Cpap · 2020 | This clinician | $1,172 |
| Takeda Pharmaceuticals U.S.A., Inc. · A Dose-Blind Extension Study With Double-Blind, Placebo-Controlled, Randomized Withdrawal Period To Evaluate the Safety and Explore the Pharmacokinetics and Pharmacodynamics of Tak-994 in Adults With Narcolepsy With Cataplexy (Narcolepsy Type 1) · 2025 | This clinician | $992 |
| Takeda Pharmaceuticals U.S.A., Inc. · A Phase 1b Randomized, Double-Blind, Placebo-Controlled, Crossover Study of 2 Single Intravenous Infusion Doses of Tak-925 in Subjects With Obstructive Sleep Apnea Who Are Experiencing Excessive Daytime Sleepiness Despite Adequate Use of Cpap · 2019 | This clinician | $921 |
| Vanda Pharmaceuticals Inc. · Evaluating the Effects of Tasimelteon Vs. Placebo in Delayed Sleep-Wake Phase Disorder (Dswpd) · 2024 | Their institution | $720 |
| JAZZ PHARMACEUTICALS INC. · A Double-Blind, Placebo-Controlled, Randomized Withdrawal, Multicenter Study of the Efficacy and Safety of Jzp-258 in the Treatment of Idiopathic Hypersomnia (Ih) With An Open-Label Safety Extension · 2019 | Their institution | $309 |
| Takeda Pharmaceuticals U.S.A., Inc. · A Study To Assess the Frequency and Characteristics of Wake and Sleep State Transitions Over Multiple Nights in Subjects With Narcolepsy Type 1 Compared With Healthy Subjects Using A Portable Electroencephalogram Device · 2020 | This clinician | $261 |
| Merck Sharp & Dohme LLC · Clinical Trial To Characterize Symptoms of Excessive Daytime Sleepiness Following Treatment Withdrawal in Participants With Narcolepsy Type 1 · 2022 | Their institution | $18 |
Checkups this office reported
Medicare did not publish checkup rates for this clinician.
- Medicare’s overall office score
- 76.5 / 100
- Scores the office’s reporting and systems. It is not a grade for how the doctor treats you.
Professional record
- NPI
- 1023151800
- Licence
- CA A67085California A67085: Current · expires 2026-12-31
- Group
- Stanford Health Care
- Gender
- Male
More record details
- Sole proprietor
- No
- Taxonomy
- Federal specialty code 2084S0012X (2084S0012X)
- Mailing address
- 300 Pasteur Dr, Stanford, CA, 94305
- NPI first listed
- 2007-02-14
- NPI last updated
- 2024-04-29
- NPI record certified
- 2024-04-29
This is when the NPI record was last certified, not a medical board exam.